con segment
color pharma medic segment hand key item point
cah guidanc today drive lower expect outlook
pharma side manag emphas contract renew larg retail
partner largest downward driver cah pharma ebit outlook
impact gener deflat biggest issu past
year larg expect given size contract absolut
result context ebit hsd ldd segment still quit notabl
indic lower gener profit y/i basi despit improv
gener deflat brand inflat expect in-lin opioid
compani indic litig expens expect rise mln
mln howev expect manag discuss notion
possibl opioid legal settlement report bloomberg yesterday report
bln opioid settlement rang larger investor expect
medic ebit medic neg impact one-tim charg relat
distribut agreement estim charg like worth mln
medic ebit includ non-gaap result current guidanc ldd
growth medic ebit suggest medic ebit would flat slightli
exclud charg line investor mute expect
segment ahead today print medic segment also benefit
mln overal cost save program seemingli much mln
benefit proport size segment instead would
drastic differ either side within segment
lower ep pt follow today earn guidanc lower
ep forecast mainli due trim
pharma distribut margin reflect greater impact custom renew
previous includ corpor cost cut major chang also lower
pt base price-to-earnings lower ep
quarterli annual ep usd
consensu number refinitiv receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
lower usd
return equiti ttm
link barclay live interact chart
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
equal weight equal weight
compani continu go transit relat
medic busi core drug distribut
busin continu lap headwind gener
upsid case see gener price improv
brand inflat come slightli expect
lead multipl expans
heavili deflationari slower expect
improv cordi busi lead
lower price multipl contract
effect tax expens dilut mlncapit mlnpharma segmentrevenu growthmsd growthprofit ebit growthhsd ldd declinegener pricingbrand pricingsimilar msd medic segmentrev growthlsd growthebit growthldd mln save barclay cardin
 quarterli revenu model mil cahcahcahcahrevenu revenuepharmaceut distribut elimin growthpharmaceut distribut elimin total revspharmaceut distribut elimin quarterli oper profit mil cahcahcahcahoper profit ebit ebit ebit ebit barclay
 quarterli incom statement distribut sell addback oper addback check excl intang asset ens rate minor check ep fulli dilut share growth distribut sell per barclay
 annual revenu model mil cahcahcahcahrevenu revenuepharmaceut distribut elimin growthpharmaceut distribut elimin total revspharmaceut distribut elimin annual oper profit mil cahcahcahcahoper profit ebit ebit ebit ebit barclay
 annual incom statement distribut sell addback oper addback check excl intang asset ens rate minor check ep fulli dilut share growth distribut sell per barclay
steve valiquett herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli relat
specif recommend view express research report
barclay research produc invest bank barclay bank plc affili collect individu barclay
author contribut research report research analyst unless otherwis indic public date top report
reflect local time report produc may differ releas date provid gmt
avail disclosur
compani subject research report current import disclosur regard compani pleas refer
http //publicresearch barclay com altern send written request barclay research complianc seventh avenu floor
new york ny call
analyst respons prepar research report receiv compens base upon variou factor includ firm total
revenu portion gener invest bank activ profit revenu market busi
potenti interest firm invest client research respect asset class cover analyst
analyst regularli conduct site visit view materi oper cover compani barclay polici prohibit accept
payment reimburs cover compani travel expens visit
barclay research depart produc variou type research includ limit fundament analysi equity-link analysi
quantit analysi trade idea recommend contain one type barclay research may differ contain
type barclay research whether result differ time horizon methodolog otherwis
http //publicresearch barcap com/s/rd htm order access barclay research conflict manag polici statement pleas refer
procedur pleas
price sourc refinitiv last avail close price relev trade market unless anoth time sourc indic
